title: Does rituximab really induce hepatitis C virus reactivation?
authors.forename: Daisuke
authors.initials: D
authors.lastname: Ennishi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yokoyama
authors.forename: Yasuhito
authors.initials: Y
authors.lastname: Terui
authors.forename: Kengo
authors.initials: K
authors.lastname: Takeuchi
authors.forename: Kazuma
authors.initials: K
authors.lastname: Ikeda
authors.forename: Mitsune
authors.initials: M
authors.lastname: Tanimoto
authors.forename: Kiyohiko
authors.initials: K
authors.lastname: Hatake
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects*; D006258:Head and Neck Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D016174:Hepacivirus / Q000502:physiology*; D006526:Hepatitis C / Q000821:virology*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008297:Male; D049268:Positron-Emission Tomography; D012367:RNA, Viral / Q000032:analysis; D000069283:Rituximab; D014057:Tomography, X-Ray Computed; D014775:Virus Activation / Q000187:drug effects*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D012367:RNA, Viral; D000069283:Rituximab